^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ

    Company:
    Adaptive Biotech
    1d
    DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, David Avigan
    New P1 trial
    |
    CSF2 (Colony stimulating factor 2)
    |
    clonoSEQ
    2d
    Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL. (PubMed, Am J Case Rep)
    Supportive care included epoetin alfa, romiplostim, iron, and vitamin supplementation. CONCLUSIONS This is the first known reported case that demonstrates the feasibility and effectiveness of a chemotherapy-free induction strategy using inotuzumab and blinatumomab for frontline treatment of Ph-negative B-ALL in Jehovah's Witness patients. It shows that MRD negativity can be safely achieved without cytotoxic chemotherapy or transfusion support and supports the use of the ALLIANCE A041703 trial regimen as a treatment model for this unique and underserved patient group.
    Journal • Minimal residual disease
    |
    clonoSEQ
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Nplate (romiplostim)
    4d
    VENETOSTOP: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ
    |
    Venclexta (venetoclax)
    12d
    MAVRiC: Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, AstraZeneca | Trial completion date: Nov 2032 --> May 2029 | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Nov 2032 --> May 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation • IGH mutation
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    12d
    Avo In R/R And Previously Untreated MCL (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Austin I Kim | N=53 --> 72 | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    26d
    NIRVANA: Non-invasive MRD Assessment in Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=36, Completed, Rajshekhar Chakraborty, MD | Recruiting --> Completed | N=88 --> 36 | Trial completion date: Jun 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Liquid biopsy • Minimal residual disease
    |
    clonoSEQ
    26d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    27d
    Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)
    P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(11q)
    |
    clonoSEQ
    |
    Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)
    27d
    ESR-23-22182: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL (clinicaltrials.gov)
    P2, N=62, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(11q)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)
    1m
    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, University of Alberta
    New P2 trial
    |
    clonoSEQ
    |
    Iclusig (ponatinib)
    1m
    MagnetisMM-7: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (clinicaltrials.gov)
    P3, N=811, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    clonoSEQ
    |
    lenalidomide • Elrexfio (elranatamab-bcmm)
    1m
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=283, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • etentamig intravenous (ABBV-383 IV)